fda glp-1 warning news november 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of A network meta-analysis backed weight-loss
Description
Confused about Medicare GLP-1 program eligibility
Trusted by 70,000+ customers worldwide
Food and Drug Administration has not
Wegovy's high cost leaves many people searching for affordable GLP-1 therapy
Learn how to fuel your body with the right balance of nutrients to preserve muscle, boost energy, and achieve sustainable weight loss
In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase I development.
